MAP1LC3B and metabolic dysfunction-associated steatohepatitis: In contrast, treatment with BM-MSCs-EV (120 μg/kg) or BM-MSCs significantly increased LC3B protein expression by 81% as compared to cardiotoxicity induced by NASH group (Figure 5C).